Key result
Higher arterial stiffness, estimated by the augmentation index, independently predicted all-cause mortality in individuals with type 1 diabetes (standardized HR 1.71; 95% CI 1.10-2.65; P=0.017).
Why the study?
Type 1 diabetes carries a significant CVD burden poorly explained by traditional risk factors, prompting investigation into whether arterial stiffness estimated by the augmentation index predicts mortality.
Does arterial stiffness estimated by augmentation index predict mortality in individuals with type 1 diabetes?
Cohort (n=906)
Does arterial stiffness estimated by augmentation index predict mortality in individuals with type 1 diabetes?
Hazard Ratio: 1.71 (95% CI 1.1–2.65)
p-value: p=0.017
Arterial stiffness, measured by augmentation index, is an independent predictor of all-cause and cardiovascular/diabetes-related mortality in patients with type 1 diabetes.
AIx may refine mortality risk stratification in type 1 diabetes beyond traditional factors; hypothesis-generating for prospective trials.
OBJECTIVE Type 1 diabetes is accompanied by a significant burden of cardiovascular disease (CVD), which is poorly explained by traditional risk factors. We therefore aimed to explore whether arterial stiffness estimated by the augmentation index (AIx) predicts mortality in individuals with type 1 diabetes. RESEARCH DESIGN AND METHODS After baseline examination comprising pulse wave analysis by applanation tonometry alongside assessment of traditional cardiovascular risk factors, 906 individuals with type 1 diabetes from the Finnish Diabetic Nephropathy (FinnDiane) Study were followed up for a median of 8.2 years (interquartile range 5.7–9.7). Associations between baseline hemodynamics, including AIx, and all-cause mortality as well as a composite of cardiovascular and/or diabetes-related mortality were investigated using multivariable Cox regression models. RESULTS The 67 individuals who died during follow-up had higher baseline AIx (median 28% [interquartile range 21–33] vs. 19% [9–27]; P < 0.001) compared with those alive. This association was independent of conventional risk factors (age, sex, BMI, HbA1c, estimated glomerular filtration rate [eGFR], and previous CVD event) in Cox regression analysis (standardized hazard ratio 1.71 [95% CI 1.10–2.65]; P = 0.017) and sustained in a subanalysis of individuals with chronic kidney disease. Similarly, higher AIx was associated with the composite secondary end point of cardiovascular and diabetes-related death (N = 53) after adjustments for sex, BMI, eGFR, previous CVD event, and height (standardized hazard ratio 2.30 [1.38–3.83]; P = 0.001). CONCLUSIONS AIx predicts all-cause mortality as well as a composite cardiovascular and/or diabetes-related cause of death in individuals with type 1 diabetes, independent of established cardiovascular risk factors.
No takes yet. Share an insight, caveat, or question.
Tynjälä et al. (2020) conducted a cohort in Type 1 diabetes (n=906). Arterial stiffness (augmentation index) vs. Lower arterial stiffness was evaluated on All-cause mortality (standardized HR 1.71, 95% CI 1.10-2.65, p=0.017). Higher arterial stiffness, estimated by the augmentation index, independently predicted all-cause mortality in individuals with type 1 diabetes (standardized HR 1.71; 95% CI 1.10-2.65; P=0.017).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: